This phase II trial studies how well the addition of 18F-DOPA (amino acid) positron emission tomography (PET)/computed tomography (CT) to standard of care (SOC) imaging can improve the clinical management of patients with brain tumors in over 50% of cases. PET is an imaging test that helps to measure the information about functions of tissues and organs within the body. A PET scan uses a radioactive drug (radiotracer) to show this activity. CT scan uses X-rays to create images of the bones and internal organs within the body. Combining a PET scan with a CT scan can help make the images easier to interpret. PET/CT scans are hybrid scanners that combine both of the two modalities into a single scan. This allows images of both anatomy (CT) and function (PET) to be taken during the same scan. The 18F-DOPA PET/CT scan is done with a very small amount of a radioactive tracer called FDOPA. The PET/CT scan is then used to detect the location of tumors. Using the 18FDOPA-PET/CT scan in addition to the SOC scan may improve the clinical management of patients with brain tumors.

开始日期2024-11-11

申办/合作机构

Mayo Clinic

NCT05103618

/ Not yet recruiting临床2期IIT

Evaluating the Physiological and Psychological Effects of a Novel Meditation Technique on Cerebral Activity Measured With Functional Magnetic Resonance Imaging(fMRI) and F-18 Fluorodopa PET Imaging

The purpose of this research is to use 18 F Fluorodopa positron emission tomography (FDOPA PET) to measure dopamine function, and utilize magnetic resonance imaging (MRI) to measure inflammatory and oxidative stress markers in persons with Parkinson's disease.
The overall goal of this study will be to further the understanding of the effects of a novel meditation technique called orgasmic meditation (OM) on these neurophysiological parameters.

开始日期2024-09-01

申办/合作机构

Thomas Jefferson University

NCT05512403

/ Recruiting临床3期IIT

Evaluation of Diagnostic Performances of 18F-FDOPA PET KInetics as Biomarkers for the Improvement of Care of MRI Non-contrast Enhanced Gliomas

the investigators hypothesise that 18F-FDOPA PET kinetic parameters are good biomarkers to characterise suspected LGG brain lesions that exhibit no contrast on MRI, for identifying aggressive lesions. These parameters could constitute diagnostic biomarkers for this indication. This new diagnostic tool could enhance patient care in the short term in an evolving pathology affecting socially active subjects with a poor prognosis

开始日期2023-06-13

申办/合作机构

Centre Hospitalier Regional de Nancy

100 项与氟[18F]多巴相关的临床结果

登录后查看更多信息

100 项与氟[18F]多巴相关的转化医学

登录后查看更多信息

100 项与氟[18F]多巴相关的专利（医药）

登录后查看更多信息

646

项与氟[18F]多巴相关的文献（医药）

2025-02-01·INTERNAL MEDICINE JOURNAL

Clinical utility of ¹⁸F‐fluorodopa positron emission tomography in the movement disorder clinic: an Australian experience

Article

作者: Yeow, Dennis ; Adam, Robert ; Hynard, Shane ; Thomas, Paul ; Fielder, Matthew ; Katz, Matthew ; Lehn, Alexander ; O'Sullivan, John D.

Abstract:

Background:

Differentiating idiopathic Parkinson disease (iPD) from other causes of tremor and parkinsonism based on clinical grounds can be challenging, particularly early in the course of disease or in the case of atypical clinical presentations. 18F‐fluorodopa (F‐DOPA) is a positron emission tomography (PET) radioligand that can be used to demonstrate the presence and pattern of striatal presynaptic dopaminergic deficit and, thus, assist in the diagnosis of iPD and related disorders.

Aims:

To determine the clinical utility of F‐DOPA PET in an Australian movement disorder clinic setting.

Methods:

Retrospective cohort study of movement disorder clinic patients referred for F‐DOPA PET by four movement disorder neurologists over a 10‐year period to a single Australian nuclear medicine centre. Results of F‐DOPA PET scans were correlated with changes in provisional diagnosis and management in the short term following review of F‐DOPA PET results.

Results:

A total of 105 F‐DOPA PET scan results and patient records were examined. In this cohort, provisional clinical diagnosis was altered in 37.9% of patients, and changes to clinical management were made in 48.4% of patients in the short term following review of F‐DOPA PET results. Changes in both diagnosis and management were more common following a normal F‐DOPA PET scan result (42.4% and 53.0% respectively) than a scan consistent with iPD (23.5% and 32.4% respectively).

Conclusions:

There was significant change in provisional clinical diagnosis and management in the short term following review of F‐DOPA PET results indicating significant clinical utility of F‐DOPA PET in the Australian movement disorder clinic setting.

2024-12-01·LANCET ONCOLOGY

Short-course hypofractionated proton beam therapy, incorporating 18F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial

Article

作者: Liu, Wei ; Ruff, Michael ; Uhm, Joon ; Ashman, Jonathan ; Voss, Molly ; Kizilbash, Sani ; Hu, Leland ; Yang, Ming ; Mrugala, Maciej ; Buras, Matthew ; Porter, Alyx ; Bendok, Bernard ; Breen, William ; Brown, Paul ; Vora, Sujay ; Sio, Terence ; Laack, Nadia ; Brinkmann, Debra ; Mahajan, Anita ; Pafundi, Deanna

BACKGROUND:

Older patients (aged ≥65 years) with glioblastoma have a worse prognosis than younger patients and a median overall survival of 6-9 months. 3,4-Dihydroxy-6-[¹⁸F]fluoro-L-phenylalanine (¹⁸F-DOPA) PET sensitively and specifically identifies metabolically active glioblastoma for preferential targeting. Proton beam therapy potentially improves quality of life (QOL) by sparing more healthy brain tissue than photon radiotherapy. With improved targeting and the dosimetric advantages of proton beam therapy, we aimed to test whether hypofractionated proton beam therapy could improve survival and QOL in older patients with glioblastoma.

METHODS:

In this single-arm phase 2 trial, we enrolled patients aged 65 years and older with an Eastern Cooperative Oncology Group performance status score of 0-2 and newly diagnosed WHO grade 4, malignant glioblastoma from two Mayo Clinic campuses (Phoenix, AZ, and Rochester, MN, USA). Radiotherapy target volumes were defined by ¹⁸F-DOPA PET and MRI regions of contrast enhancement. Patients were given dose-escalated hypofractionated proton beam therapy (35-40 Gy equivalents in five or ten treatments) plus oral concurrent temozolomide (75 mg/m² daily on days 1-7 for the five-treatment regimen or on days 1-14 for the ten-treatment regimen), and 1 month after completing radiotherapy patients were given adjuvant temozolomide (150-200 mg/m² on days 1-5 for six 28-day cycles). The primary endpoint was overall survival at 12 months after enrolment. The primary endpoint and safety were assessed in the intention-to-treat population (defined as all eligible patients who started radiotherapy). This study is registered with ClinicalTrials.gov, NCT03778294, and is now complete.

FINDINGS:

Between May 22, 2019, and May 25, 2021, 43 patients were enrolled, of whom four did not receive treatment because of progression (n=2), death (n=1), or insurance denial (n=1), such that 39 patients received treatment (median age 70·2 years [IQR 67·4-74·3]; 11 [28%] of 39 patients were female, 28 [72%] were male, 37 [95%] were White, one [3%] was Black or African American, and one chose not to disclose their race). As of data cutoff (Jan 30, 2024), median follow-up was 25·4 months (IQR 22·1-29·7). 22 (56% [95% CI 39-72]) of 39 patients were alive at 12 months. Median overall survival was 13·1 months (95% CI 11·1-19·1). Grade 3 baseline-adjusted, treatment-associated adverse events were CNS necrosis (four [10%] of 39) and thrombocytopenia (one [3%]). No baseline-adjusted, treatment-associated grade 4 adverse events or deaths occurred.

INTERPRETATION:

We observed improved overall survival compared with historical controls and a promising adverse event profile by using ¹⁸F-DOPA PET-guided, dose-escalated, hypofractionated proton beam therapy. These findings have resulted in the opening of a phase 2 study (NCT05781321) investigating this regimen versus standard-of-care treatment in adults of any age with newly diagnosed glioblastoma.

FUNDING:

Mayo Clinic Marley Endowment Funds and the Lawrence W and Marilyn W Matteson Fund in Cancer Research.

2024-10-01·PARKINSONISM & RELATED DISORDERS

Early detection of dopaminergic dysfunction and glymphatic system impairment in Parkinson's disease

Article

作者: Chen, Yu-Chen ; Yao, Jun ; Shang, Song'an ; Yin, Xindao ; Huang, Ting ; Tian, Youyong ; Zhao, Hongdong ; Li, Rushuai

PURPOSE:

This study aimed to assess the glymphatic function and its correlation with clinical characteristics and the loss of dopaminergic neurons in Parkinson's disease (PD) using hybrid positron emission tomography (PET)-magnetic resonance imaging (MRI) combined with diffusion tensor image analysis along the perivascular space (DTI-ALPS), choroid plexus volume (CPV), and enlarged perivascular space (EPVS) volume.

METHODS:

Twenty-five PD patients and thirty matched healthy controls (HC) participated in the study. All participants underwent ¹⁸F-fluorodopa (¹⁸F-DOPA) PET-MRI scanning. The striatal standardized uptake value ratio (SUVR), DTI-ALPS index, CPV, and EPVS volume were calculated. Furthermore, we also analysed the relationship between the DTI-ALPS index, CPV, EPVS volume and striatal SUVR as well as clinical characteristics of PD patients.

RESULTS:

PD patients demonstrated significantly lower values in DTI-ALPS (t = 3.053, p = 0.004) and larger CPV (t = 2.743, p = 0.008) and EPVS volume (t = 2.807, p = 0.008) compared to HC. In PD group, the ALPS-index was negatively correlated with the Unified Parkinson's Disease Rating Scale III (UPDRS-III) scores (r = -0.730, p < 0.001), and positively correlated with the mean putaminal SUVR (r = 0.560, p = 0.007) and mean caudal SUVR (r = 0.459, p = 0.032). Moreover, the mean putaminal SUVR was negatively associated with the UPDRS-III scores (r = -0.544, p = 0.009).

CONCLUSION:

DTI-ALPS has the potential to uncover glymphatic dysfunction in patients with PD, with this dysfunction correlating strongly with the severity of disease, together with the mean putaminal and caudal SUVR. PET- MRI can serve as a potential multimodal imaging biomarker for early-stage PD.

项与氟[18F]多巴相关的新闻（医药）

2025-01-22

·小核说核药

“罕见”的甲状腺髓样癌核药赛道

01. 背景简介相关往期链接：甲状腺髓样癌的新型诊疗核药！ JNM：CCK2R靶点新核药！ Nature：创新的共价核药闪亮登场！新的FAP探针：DO3A.Glu.(FAPi)2和DOTAGA.Glu.(FAPi)2.！甲状腺髓样癌（medullary thyroid carcinoma, MTC）起源于甲状腺滤泡旁细胞，为常见神经内分泌肿瘤，恶性程度介于分化型甲状腺癌与间变性甲状腺癌之间，常伴有降钙素（calcitonin, Ctn）水平增高，易出现淋巴结转移、远处转移。MTC的发病率仅占所有甲状腺癌的1%-2%，但其死亡率却高达14%-17%，甲状腺髓样癌的早期诊断非常重要。目前MTC的诊断仍以病史询问、体格检查、影像学检查（彩超、CT、MRI、核医学检查如甲状腺显像及PET/CT全身扫描）、实验室检查（Ctn、CEA）和FNA病理为主。外科手术是MTC惟一的根治性治疗方式，手术指征近年来无明显变化，主要的争议集中于预防性颈部淋巴结清扫的指征和范围，因此完善的MTC治疗策略是一种综合治疗，建立在详细的全身评估基础上，需要在合适的治疗时机联合应用多种治疗手段。核医学科在MTC的管理中具有重要意义，通过多种PET/CT示踪剂（如18F-DOPA、18F-FDG和68Ga-生长抑素受体显像剂）的应用，核医学显像不仅能够实现对MTC的早期诊断和精准分期，还能有效监测治疗反应和疾病复发。这些示踪剂通过靶向肿瘤细胞的特定分子标志物（如氨基酸转运蛋白、葡萄糖代谢通路和生长抑素受体），为MTC的分子机制研究提供了可视化手段，并助力个性化治疗方案的制定。此外，新核药的开发和应用还为靶向放射性治疗提供了可能，进一步拓展了MTC的治疗策略。总之，核药在MTC的诊断、治疗和预后评估中发挥着不可替代的作用，是未来精准医学的重要发展方向。 02. [68Ga]Ga-CTR-FAPI 2024年5月，Nature期刊在线发表了题为Covalent Targeted Radioligands Potentiate Radionuclide Therapy 的研究论文，（Nature：创新的共价核药闪亮登场！）突破了成纤维细胞活化蛋白（FAP，为泛癌种靶点）靶向放射配体因肿瘤摄取、滞留不足导致疗效不佳的瓶颈问题，有望改写相关疾病的临床诊疗指南。在2024 ASCO年会上，中国医学科学院肿瘤医院头颈外科的刘绍严教授主持的研究“Covalent FAPI PET enables accurate management of medullary thyroid carcinoma: A prospective single-arm comparative clinical trial”作为最新突破摘要（LBA）口头报告，引起了全球肿瘤学界的广泛关注，研究发现，甲状腺髓样癌的肿瘤基质中存在着高表达的FAP，通过靶向FAP的小分子药物FAPI，能够高度选择性地识别甲状腺髓样癌病灶，并实现更精准的诊疗。在这项临床研究中，共价纤维细胞激活蛋白抑制剂（FAPI）技术展现出了显著的临床优势。与传统诊断手段相比，共价FAPI技术不仅实现了高达98%的病灶检出率，还呈现出卓越的病灶摄取能力（肿瘤/背景比值T/N ratio高达6.20 ± 5.52），其诊断准确性更是高达96.7%。这一创新技术为超过60%的甲状腺髓样癌患者带来了直接的临床获益，尤其在手术患者中，通过精准界定病灶范围，显著优化了手术方案，进而提升了肿瘤的治愈率。这些令人瞩目的数据不仅凸显了共价FAPI技术在甲状腺髓样癌精准诊疗中的巨大潜力，更为甲状腺髓样癌的精准诊疗奠定了坚实的基础。 2024年10月，这项研究结果正式在Cancer discovery期刊发表，题为“CTR-FAPI PET enables precision management of medullary thyroid carcinoma”。研究对 50 名 MTC 患者进行了[68Ga]Ga-CTR-FAPI PET-CT 和[18F]FDG PET-CT 的头对头比较，系统评估了这种新型的共价靶向放射性配体[68Ga]Ga-CTR-FAPI PET-CT在甲状腺髓样癌（MTC）患者中的检测效果。研究结果显示，[68Ga]Ga-CTR-FAPI PET-CT在患者水平的检测率显著高于[18F]FDG PET-CT（98% vs. 66%），并且[68Ga]Ga-CTR-FAPI PET-CT在肿瘤摄取量（SUVmax）和诊断准确性方面也展现出优越性（96.7% vs. 43.3%）。此外，32%的患者根据[68Ga]Ga-CTR-FAPI PET-CT改变了治疗方案，66.7%的患者改变了手术计划。总之，这些发现表明[68Ga]Ga-CTR-FAPI PET-CT在MTC的检测和诊断中具有潜在的临床应用价值，能够提供更精准的疾病管理，有潜力成为MTC患者成像的新标准！ 03. [68Ga]Ga-DOTA-MGS5 胆囊收缩素-2受体（Cholecystokinin-2 Receptor, CCK2R）在多种人类癌症中呈现高表达，包括髓样甲状腺癌（Medullary Thyroid Carcinoma, MTC）、小细胞肺癌（Small Cell Lung Cancer, SCLC）、星形细胞瘤（Astrocytoma）、卵巢间质瘤（Stromal Ovarian Cancer）以及胃肠胰腺神经内分泌肿瘤（Gastroenteropancreatic Neuroendocrine Tumors, NETs）等。CCK2R的高表达使其成为肿瘤诊断和治疗的潜在靶点。尽管已有针对CCK2R的放射性标记肽的临床前研究，但自1990年代末以来，相关的临床研究较少。近年来，新的CCK2R靶向肽类似物被开发出来，显示出良好的临床转化潜力。 2019年7月，《核医学杂志》（Journal of Nuclear Medicine [JNM]）上发表的一篇研究成功开发并评估了这一新型CCK2R靶向肽类似物DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-NH2 (DOTA-MGS5)，旨在优化其在转移性MTC及其他CCK2R表达恶性肿瘤中的靶向性能。研究结果显示，DOTA-MGS5在不同介质中表现出显著的抗酶降解能力，且在小鼠体内具有良好的代谢稳定性。该肽类似物对CCK2R具有高亲和力，并在A431-CCK2R细胞中显示出教高的摄取。在荷瘤小鼠的研究中，DOTA-MGS5展现出教高的肿瘤摄取和教理想的肿瘤/肾脏比值，表明DOTA-MGS5具有优异的靶向特性，有望未来在进展性或转移性MTC及其他CCK2R表达恶性肿瘤中进行临床转化研究（已被商业孵化）。 2025年1月，这项研究结果正式在Journal of Nuclear Medicine期刊发表，题为“Safety, Biodistribution, and Radiation Dosimetry of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors”。该研究纳入了12名患者，揭示了68Ga-DOTA-MGS5在6名晚期MTC患者和6名其他神经内分泌肿瘤（NETs）患者中进行的前瞻性I/IIA期临床试验（clinicaltrials.gov NCT06155994）研究结果，系统评估了探针在MTC和其他NETs患者中的安全性、生物分布、辐射剂量学以及成像效果。研究结果显示68Ga-DOTA-MGS5的给药耐受性良好，仅在3名患者中观察到轻微的药物不良反应，这些反应均为一过性且无需干预。药代动力学研究显示，探针在注射后215分钟时，血液中残留的放射性活性低于21%，表明其从血液中快速清除且主要通过肾脏排泄，注射后3小时内尿液累积排泄率超过56.9%。辐射剂量学计算显示，膀胱壁、胃壁和肾脏的吸收剂量最高，全身有效剂量为0.023±0.007 mSv/MBq，这一剂量水平与68Ga标记的其他肽类似物相当。注射后1小时和2小时为最佳PET成像时间点，2小时TBRs更高。这些结果证实了68Ga-DOTA-MGS5在CCK2R靶向成像中的潜力，为未来在MTC和其他CCK2R表达肿瘤中的临床应用提供了有力支持，目前治疗核药也在快速推进中，未来将有更多的数据证明其应用价值。 04. 18F-FAPI-FUSCC 2024年10月30日，复星医药与复旦大学附属肿瘤医院举行了“泛实体瘤靶向诊疗一体化放射性药物专利及技术转让”签约仪式。双方将借助复星医药在创新和全球化方面的全产业链资源优势，并依托复旦大学附属肿瘤医院领先的学科优势，加速科研成果转化。这项由医院核医学科主任宋少莉教授领衔的“泛实体瘤靶向诊疗一体化放射性药物项目”专利技术成功实现转化，也是我国首个泛肿瘤类型的靶向放射性诊疗一体化药物专利技术的院企转化，成果转化签约总价待所有里程碑达成后最高可达人民币5,000万元。复旦大学附属肿瘤医院虞先濬院长，复星国际联席CEO、复星医药非执行董事陈启宇先生出席签约仪式并讲话。签约仪式由陈震副院长主持，复星医药创新药事业部CSO、全球研发中心联席总裁李翔代表公司签约，复旦大学附属肿瘤医院核医学科宋少莉主任对该项目合作做了进一步介绍。图片及上一段内容源自：5000万元！肿瘤医院“泛实体瘤靶向诊疗一体化放射性药物”专利技术实现转化相关专利的当前申请(专利权)人变更为上海复星医药产业发展有限公司，同系列结构[68Ga/177Lu]Ga/Lu-FAPI-FUSCC-I/II相关研究成果于2024年2月发表于Molecular Pharmaceutics期刊，名为“Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [68Ga]Ga-FAPI-FUSCC-II”。研究结果显示[68Ga]Ga-FAPI-FUSCC-II显示出比[68Ga]Ga-FAPI-FUSCC-I和[68Ga]Ga-FAPI-04更高的肿瘤摄取和更高的肿瘤/非靶比值。体外生物分布结果与生物分布结果一致。临床[68Ga]Ga-FAPI-FUSCC-II-PET/CT成像进一步证明了其良好的生物分布和动力学，原发性肿瘤（SUVmax，12.17 ± 6.67）和远处转移（SUVmax，9.24 ± 4.28）的摄取较高，显示出比[68Ga]Ga-FAPI-04更高的肿瘤摄取与滞留。 2024年09月12日，注册号为ChiCTR2400089672的临床研究信息显示：这是一项评估18F-FAPI-FUSCC PET/CT对甲状腺髓样癌诊断分期价值的前瞻性、开放性、单臂、单中心研究，目的是通过单中心临床研究进一步确证18F-FAPI-FUSCC PET/CT对MTC诊断、分期的优势，弥补18F-FDG对MTC应用中的不足，复旦大学附属肿瘤医院核医学科宋少莉主任为本研究的研究者，目标入组人数为40人，待研究结果公布将做后续跟踪介绍。 05. 小结 MTC的发病率低，相对“小众”，药企资本及公共财政对其关注也相对有限。能发现并聚焦到真正关键的临床问题已属不易，兼顾“小众”的临床需求构建可持续的核药商业/盈利模式，对于打造成功的产品（临床价值 + … + 市场成功）同样重要。期待新核药在MTC诊疗转化研究中取得更多突破，实现临床与市场双赢。 ●新CLDN18.2靶向核药重磅来袭！ ●68Ga-FAP-2286精准诊断尿路上皮癌！ ●新TROP2靶向核药重磅来袭！ ●你单位中秋节发啥了？戳“小核”一起来讨论吧!

ASCO会议临床1期临床结果

2024-05-31

·同写意

拜耳帕金森病细胞疗法候选药物获美国FDA再生医学先进疗法认定丨会员动态

突破性疗法临床1期加速审批

2024-05-31

·Pharmaceutical Technology

FDA grants RMAT status for BlueRock’s Parkinson’s therapy

Bemdaneprocel is created to replace the dopamine-producing neurons lost due to Parkinson’s disease. Credit: Annick Vanblaere from Pixabay. The US Food and Drug Administration (FDA) has granted a regenerative medicine advanced therapy (RMAT) designation for BlueRock Therapeutics’ investigational cell therapy bemdaneprocel (BRT-DA01) for Parkinson’s disease. Recommended Buyer's Guides Buyer's Guide Leading Guide to Packaging Materials, Containers and Containment Services for the Pharmaceutical Industry Buyer's Guide Top Guide for Drug Delivery Systems BlueRock is a wholly owned independently operated Bayer subsidiary. Bemdaneprocel is claimed to be the most clinically advanced cell therapy for Parkinson’s disease treatment in the US. The therapy is created to replace the dopamine-producing neurons lost in the course of the disease. It was assessed in the multi-site, multicentre, non-randomised, open-label, non-controlled study. See Also: Dupixent gets closer to EU approval as the FDA delays its decision on COPD Bristol Myers Squibb’s Breyanzi gains FDA approval for lymphoma The trial involved 12 subjects diagnosed with Parkinson’s disease who underwent surgical transplantation of bemdaneprocel cells into the post-commissural putamen bilaterally, followed by a one-year immunosuppression regimen. Data from the trial, announced in March 2024, indicated that bemdaneprocel was well tolerated and did not present major safety issues up to 18 months post-treatment. Furthermore, an increase in the F-DOPA PET imaging signal was observed after the cessation of immune suppression therapy at 12 months, suggesting that the transplanted cells survive and engraft in the brain. The RMAT designation is managed by the FDA’s Center for Biologics, Evaluation and Research (CBER). It is specifically for investigational regenerative therapies, including cell therapies, aimed at treating, modifying, reversing or curing serious ailments. Therapies granted RMAT status can benefit from expedited development review and development planning guidance from senior CBER managers. This status also facilitates early discussions about possible surrogate endpoints and strategies to support accelerated approval and satisfy post-approval needs. BlueRock Therapeutics president and CEO Seth Ettenberg stated: “We are excited about the positive data from the bemdaneprocel Phase I clinical trial and believe it has great potential to help patients living with Parkinson’s disease regain functions they have lost to the disease. “Now with this RMAT designation in hand, we look forward to closely collaborating with the FDA to ready this programme for Phase II clinical studies.” Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva . Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Cell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. Thank you. You will receive an email shortly. Please check your inbox to download the Whitepaper. By Cytiva Thematic By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

临床1期细胞疗法基因疗法

100 项与氟[18F]多巴相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	氟[18F]多巴	V09IX	DB13848

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
诊断试剂	瑞士	Novartis Pharma AG	2016-11-01
帕金森障碍	瑞士	Novartis Pharma AG	2016-11-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
多系统萎缩	临床3期	中国	原子高科股份有限公司	2024-12-27
帕金森病	临床3期	中国	原子高科股份有限公司	2024-12-27
进行性核上性麻痹	临床3期	中国	原子高科股份有限公司	2024-12-27
震颤	临床3期	中国	原子高科股份有限公司	2024-12-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03778294 (Pubmed \| Lancet Oncol)	临床2期	胶质母细胞瘤	43	Hypofractionated Proton Beam Therapy + Temozolomide	選積鹹簾製餘鏇膚遞餘(築製積醖積構鑰窪窪膚) = 醖齋積顧構齋鏇鏇構繭齋簾選鹹築廠範鹹夢鹹 (遞鹽積鑰積鏇鏇蓋製製 ) 更多	积极	2024-12-01
EANM2024	N/A	神经母细胞瘤	10	123I-MIBGF-Dopa (123I-MIBG scintigraphy)	遞糧觸鬱齋範鬱衊構廠(廠夢鹽鬱鹹獵餘夢簾範) = 蓋醖觸鬱築積齋鬱簾淵淵鹹網膚構膚衊觸簾窪 (簾鹽窪範壓憲襯遞壓鏇 ) 更多	积极	2024-09-27
NCT03778294 (CTgov)	临床2期	胶质母细胞瘤	43	Proton Beam Radiation Therapy+Computed Tomography+Temozolomide	膚選築顧憲衊蓋廠膚壓(簾蓋廠鹽鏇遞憲鬱鑰選) = 繭襯襯齋願選選積鬱觸鹽窪糧壓壓積範範襯鹽 (網簾廠築鬱憲觸鏇網鑰, 憲衊襯糧糧夢壓構壓遞 ~ 網艱鹽鬱齋鹹鹽築憲鏇) 更多	-	2023-11-14
Phase II study (SNO2023)	临床2期	胶质母细胞瘤 18F-DOPA	39	18F-DOPA (GTV ≤ 65 cc)	網鹹艱構衊鬱鬱網觸積(膚醖鬱鑰範衊廠顧範網) = 鏇顧製齋餘築膚糧憲醖餘壓衊築簾觸衊鏇鹽願 (鹹夢壓鹹襯積淵獵選選 ) 更多	积极	2023-11-10
SAT555 (ENDO2023)	N/A	多发性内分泌瘤病2b型 \| 甲状腺髓样癌	26	68 Ga-DOTATATE PET/CT	蓋簾齋蓋艱遞窪廠衊廠(艱襯鹽鑰鏇獵窪鏇鏇願) = 鏇繭齋構網網築鹽築簾膚壓鏇製廠願範鹹壓鏇 (廠艱簾製網衊積窪壓繭 ) 更多	-	2023-10-05
SAT555 (ENDO2023)	N/A	多发性内分泌瘤病2b型 \| 甲状腺髓样癌	26	18 F-DOPA18 F-FDGA (18 F-FDG PET/CT)	蓋簾齋蓋艱遞窪廠衊廠(艱襯鹽鑰鏇獵窪鏇鏇願) = 糧觸網簾簾製鑰憲範衊膚壓鏇製廠願範鹹壓鏇 (廠艱簾製網衊積窪壓繭 ) 更多	-	2023-10-05
NCT03778294 (ASCO2023) 人工标引	临床2期	胶质母细胞瘤一线 MGMT	39	18F-DOPA concurrent/adjuvant temozolomide	築鹽夢夢構餘鹽壓簾蓋(獵遞簾網襯夢製餘鑰鹽) = 鏇網膚齋鏇淵襯餘廠範鏇淵製膚餘蓋醖鏇夢鹹 (顧衊鹽鬱選簾窪積遞觸 ) 达到更多	积极	2023-05-31
NCT03778294 (ASCO2023) 人工标引	临床2期	胶质母细胞瘤一线 MGMT	39	18F-DOPA concurrent/adjuvant temozolomide (MGMT methylation)	築鹽夢夢構餘鹽壓簾蓋(獵遞簾網襯夢製餘鑰鹽) = 觸淵廠鹹鑰窪積鏇鏇壓鏇淵製膚餘蓋醖鏇夢鹹 (顧衊鹽鬱選簾窪積遞觸 ) 达到更多	积极	2023-05-31
EANM2022	N/A	脑癌	55	18F-FDOPA (Primary Tumors)	鬱遞簾積廠衊壓鏇壓憲(積壓窪網襯鏇蓋製鹹構) = 顧鹹壓膚鑰鬱夢遞艱廠窪選鬱壓壓獵淵襯衊鏇 (餘簾衊構窪衊膚積簾壓 ) 更多	-	2022-09-22
EANM2022	N/A	脑癌	55	18F-FDOPA (Metastasis Tumors)	鬱遞簾積廠衊壓鏇壓憲(積壓窪網襯鏇蓋製鹹構) = 蓋艱鏇鏇網簾蓋鹹鬱築窪選鬱壓壓獵淵襯衊鏇 (餘簾衊構窪衊膚積簾壓 ) 更多	-	2022-09-22
SNMMI2022	N/A	胶质瘤	-	[18F]-FDOPA (Progression)	遞衊選窪衊壓鹽窪鬱製(選選壓鏇餘鑰選壓簾夢) = 襯膚製鏇遞鑰艱餘願簾簾鏇襯淵製鹹餘獵觸鑰 (蓋鹹醖憲夢醖選鹽鑰鬱, 9)	-	2022-08-08
SNMMI2022	N/A	胶质瘤	-	[18F]-FDOPA (Radionecrosis)	遞衊選窪衊壓鹽窪鬱製(選選壓鏇餘鑰選壓簾夢) = 淵憲醖顧淵艱築齋製願簾鏇襯淵製鹹餘獵觸鑰 (蓋鹹醖憲夢醖選鹽鑰鬱, 9)	-	2022-08-08
SNMMI2022	N/A	多发性内分泌瘤病2a型	-	68Ga-DOTATATE PET/CT	淵鹽壓糧糧築夢鹹衊遞(窪築選憲觸構憲餘壓觸) = 積艱鏇膚範膚鏇壓衊憲醖顧網築衊網膚襯築範 (襯壓壓淵淵繭繭築衊範, 51.9 ~ 95.7)	-	2022-08-08
SNMMI2022	N/A	先天性高胰岛素血症	-	[18F] DOPA18F-DOPAPA (18F-DOPA PET-CT)	廠獵膚願鑰顧廠醖選範(獵獵簾鑰鹽餘願鹽淵窪) = 鹽網齋夢鑰簾糧鹽蓋鏇構淵製夢夢膚繭鹹構餘 (鑰醖衊網糧願鏇網鬱鏇 )	-	2022-08-08